TRT and Hormone Clinic Marketing: What FTC and FDA Rules Actually Restrict

TRT and hormone clinics market into a category that overlaps FTC weight-loss and health claim rules, FDA restrictions on prescription drug advertising, and, for clinics running direct-to-consumer campaigns, a set of platform policies that treat hormone therapy with the same scrutiny as other prescription-adjacent categories.

The Symptom-List Problem in Hormone Clinic Marketing

A lot of TRT marketing leans on a checklist of vague symptoms, low energy, reduced muscle mass, mood changes, framed as clear signs of low testosterone. The FTC and FDA both scrutinize this pattern when it functions as a diagnostic quiz steering visitors toward a prescription, since it can imply a medical determination the content itself isn't actually qualified to make. Content should route toward a genuine clinical evaluation, not present the symptom list itself as a diagnosis.

What FDA Rules Restrict About Prescription Hormone Marketing

Direct-to-consumer prescription drug advertising falls under FDA oversight, which generally requires fair balance between benefits and risks, and disclosure of significant side effects when specific drug claims are made. Marketing that names a specific hormone therapy product and its benefits without any risk disclosure runs directly into this requirement, regardless of how the ad is framed.

Testimonials in Hormone Clinic Marketing Carry Extra Weight

A testimonial describing dramatic improvements in energy, mood, or physical performance functions similarly to a result claim, and needs the same substantiation and "individual results vary" framing that applies elsewhere in health marketing. Testimonials implying every patient sees similar results are one of the more common compliance gaps in this specific vertical.

Platform Ad Policy for Hormone Therapy Specifically

Google and Meta both apply healthcare-adjacent ad review to hormone therapy campaigns, and prescription-specific certification requirements often apply on top of general healthcare advertiser policy, similar to how GLP-1 marketing gets treated. Confirm current platform requirements before launching, since these policies get updated more often than most clinics expect.

Tridigiam builds hormone clinic marketing around clinical evaluation framing rather than symptom-list self-diagnosis by default. We're not a medical or legal compliance firm, and content should go through your clinical and compliance review before it publishes. For the broader picture on telehealth marketing, see our Telehealth & GLP-1 Marketing guide.

Frequently asked questions

Can a hormone clinic use a symptom checklist in its marketing?

With care. The content should route visitors toward a clinical evaluation rather than presenting the symptom list itself as a diagnosis, since framing it as diagnostic can draw FTC scrutiny.

Does hormone therapy advertising need risk disclosure like other prescription drug ads?

Yes, when specific drug claims are made, FDA rules generally require fair balance between benefits and significant risks, similar to other direct-to-consumer prescription drug advertising.

Are testimonials about energy or mood improvement risky in this category?

They need the same substantiation and individual-results-vary framing as any other health result claim. An implication that most or all patients see similar improvement is a common compliance gap.

Does TRT marketing need special ad platform certification?

Often yes, hormone therapy typically falls under healthcare-adjacent and sometimes prescription-specific ad policy on Google and Meta, similar to GLP-1 marketing requirements.